Identification of biomarkers to measure HIV-specific mucosal and systemic CD8+ T-cell immunity using single cell Fluidigm 48.48 Dynamic arrays  by Trivedi, Shubhanshi et al.
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Thirty  genes  composed  of  cytokines,  chemokines,  granzymes,  perforin  and  integrins  were  evaluated  in gut
and splenic  KdGag197–205-speciﬁc  single  CD8+ T cells  using  Fluidigm  48.48  Dynamic  arrays,  with  the  aim  of
identifying  biomarkers  to predict  effective  mucosal  and  systemic  vaccine  efﬁcacy.  The  mRNA  expression
proﬁles  were  analyzed  in  three  ways:  (i)  the  “number”  of  KdGag197–205-speciﬁc  CD8+ T cells  expressing
the  biomarker,  (ii)  “level”  of  mRNA  expression  using  principal  component  analysis  (PCA) and  (iii)  poly-
functionality  in  relation  to RANTES  expression.  In total, 21 genes  were  found  to  be  differentially  expressed
between  the  vaccine  groups  and  the  immune  compartments  tested.  Overall,  the  PCA  indicated  that  IL-
13R2  or  IL-4R  antagonist  adjuvanted  vaccines  that  previously  induced  high-avidity  mucosal/systemic
CD8+ T  cells with  better  protective  efﬁcacy,  the  “level”  of mRNA  expression,  speciﬁcally  RANTES,  MIP-1,
and  integrin  4 in  gut  KdGag197–205-speciﬁc  single  CD8+ T cells,  were  signiﬁcantly  elevated  compared
to unadjuvanted  vaccine.  Furthermore,  signiﬁcantly  elevated  granzymes/perforin  levels  were  detected
in IL-13−/− mice  given  the  unadjuvanted  vaccine,  indicating  that  the degree  of IL-13 inhibition  (total,
transient  or  no  inhibition)  can  considerably  alter  the  level  of  T-cell  activity/poly-functionality.  When
d +splenic-  and  gut-K Gag197–205-speciﬁc  CD8 T cells  were  compared,  PC1  vs. PC2  scores  revealed  that  not
only  RANTES,  MIP-1,  and  integrin  4 mRNA,  but also  perforin,  granzymes  A/B, and  integrins  1  and  2
mRNA  were  elevated  in  spleen.  Collectively,  data suggest  that  RANTES,  MIP-1,  perforin,  and  integrins
4, 1 and  7 mRNA  in single  HIV-speciﬁc  CD8+ T cells  could  be used  as  a measure  of  effective  mucosal
and  systemic  vaccine  efﬁcacy.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Unlike mucosal vaccination, systemic vaccination induces CD8+
 cell that home poorly to the mucosae (e.g. the gut, genito-
ectal or the vaginal mucosae) [1–5]. Mucosal-associated lymphoid
issues are linked to what is known as the “common mucosal
mmune system”, whereby antigenic stimulation at one site can
∗ Corresponding author at: The John Curtin School of Medical Research
JCSMR), The Australian National University, Canberra, ACT 2601, Australia.
el.: +61 2 6125 4704; fax: +61 2 61252499.
E-mail address: Charani.Ranasinghe@anu.edu.au (C. Ranasinghe).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.085
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
result in immune responses in both local and distant mucosae, as
a result of mucosal homing [6,7]. Homing of lymphocytes to spe-
ciﬁc tissues is driven by the expression of cell-surface adhesion
molecules known as integrins or chemokine receptors. Integrins
are composed of non-covalently linked  and  subunits [8] that
have the ability to pair differentially to induce unique functions.
47 interacts with mucosal addressin cell adhesion molecule-
1 (MAdCAM-1) expressed on capillary endothelial cells in the
gastrointestinal mucosae [9] and E7 interacts with E-cadherin
expressed on intestinal epithelial cells [10]. Both these molecules
can provoke lymphocyte homing to the gut mucosae [11–13]. Sim-
ilarly, chemokine receptor CCR9 promotes cell homing to the small
intestine by interacting with its receptor CCL25 (TECK), present on
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
Mice and prime-boost vaccine strategies used in this study.
Mice Prime Boost
1 BALB/c i.n. FPV-HIV i.m. VV-HIV
2  IL-13−/−* i.n. FPV-HIV i.m. VV-HIV
3  BALB/c i.n. FPV-HIV-IL-13R210** i.m. VV-HIV-IL-13R210**
4  BALB/c i.n. FPV- HIV-IL-4C118** i.m. VV- HIV-IL-4C118**
All recombinant fowlpox virus (rFPV) and recombinant vaccinia virus (rVV) con-
structs encode HIV-1 gag/pol antigens. i.n. intranasal, i.m. intramuscular. The i.n.
rFPV  was  given in a ﬁnal volume of 20–25 l, where i.m. rVV immunization was
delivered in a 100 l volume. All viruses were diluted in sterile phosphate-buffered
saline (PBS) and then sonicated, to obtain homogeneous viral suspensions before
delivery.
Note.  In previous studies *IL-13−/− mice given the control unadjuvanted vaccine
strategy [22] and **BALB/c mice given the IL-13R2 adjuvanted (IL-13R210) or
IL-4R antagonist adjuvanted (IL-4C118) HIV vaccines that transiently inhibit IL-4
and/or IL-13 were found to induce mucosal and systemic KdGag197–205-speciﬁc CD8+
T cells of higher avidity which was associated with greater cell mediated protective
stored at −20 ◦C until analysis and was diluted with dH2O (1:2)
prior to qPCR reaction. Each pre-ampliﬁed cDNA sample was  then
separated into 48 separate reactions for qPCR analysis using the316 S. Trivedi et al. / Vacc
he intestinal epithelium. 41 interacts with vascular cell adhe-
ion molecule-l (VCAM-1) and ﬁbronectin [14,15]. 41-VCAM-1
inding can mediate ﬁrm adhesion of lymphocytes to the endothe-
ium during blood cell extravasation and there is evidence that 1
ntegrins can also mediate leukocyte retention, T-cell activation and
oming to lung mucosae [16,17]. Similarly, 2 integrins consisting
f L2 (CD11a/CD18 or LFA-1), M2  (CD11b/CD18, Mac-1, CR3),
X2 (CD11c/CD18, p150, 95, CR4) and D2 (CD11d/CD18) inter-
ct with intercellular adhesion molecule-1 (ICAM-1) and induce
eukocyte adhesion, T-cell activation and homing to inﬂamed skin.
Until recently, IFN- production has been the main indicator of
rotective efﬁcacy following vaccination, but many studies have
ow shown that IFN- expression alone does not always corre-
ate with high avidity/quality CD8+ T cells and protective efﬁcacy
2,18–22]. In recent studies, elevated numbers of high-avidity poly-
unctional HIV-speciﬁc T cells have been detected in HIV elite
ontrollers compared to non-controllers [23–25], highlighting the
mportance of poly-functional CD8+ T cell immunity. In different
tudies, RANTES, MIP-1 and MIP-1 of the natural ligands for
hemokine receptor 5 (CCR5) plus perforin and granzymes have
een implicated in HIV-1 protective efﬁcacy [26–31].
In the context of an HIV-1 vaccination, the induction of effec-
ive cytotoxic CD8+ T cells that migrate to the mucosae is thought
o be of great importance in curtailing the infection. It is now well
stablished that efﬁcacy of a mucosal vaccine has to be assessed
t the mucosae, not in the blood compartment. However, identi-
ying markers that correlate with effective mucosal immunity has
een a challenging task, which has hampered the design of effec-
ive mucosal vaccines for many mucosal pathogens. Speciﬁcally,
ifﬁculties associated with obtaining enough cells from mucosal
issue (e.g. gut, rectal, vaginal biopsies) have complicated the use of
onventional techniques such as ELISpot and intracellular cytokine
taining for measuring mucosal immunity [32]. Recently, the devel-
pment of microﬂuidic devices (e.g. Fluidigm’s integrated ﬂuidic
ircuits and dynamic arrays) has enabled the measurement of mul-
iple genes expression in antigen-speciﬁc single cells [33].
Surprisingly, no study to date has evaluated a compre-
ensive panel of integrins following mucosal HIV vaccination,
specially at the single cell level. Thus, in this study, fol-
owing intranasal/intramuscular HIV prime-boost vaccination,
dGag197–205-speciﬁc Peyer’s patch and splenic single CD8+ T cells
ere sorted and the expression proﬁles of 30 different mRNAs com-
osed of cytokines, chemokines, integrins, perforin and granzymes
ere analyzed. The mRNA expression proﬁles were evaluated in
our vaccine conditions (including IL-13R2 and IL-4R antagonist
djuvanted vaccines that have shown to induce high-avidity CD8
 cells [34,35]) using Fluidigm 48.48 Dynamic array with the aim
f identifying surrogate mucosal-speciﬁc biomarkers that would
ffectively measure mucosal immunity.
. Materials and methods
.1. Immunization of mice and mucosal/systemic lymphocytes
reparation
Pathogen-free 6–8-week-old female BALB/c WT  and BALB/c
L-13 KO mice were prime-boost immunized with i.n. FPV-
IV/i.m.VV-HIV unaduvanted vaccine strategy or IL-13R2-
djuvant or IL-4R antagonist adjuvant vaccine strategies as in
able 1 [34,35], under isoﬂurane anesthesia two weeks apart sim-
lar to our previous studies [2,22,34,35]. To measure systemic and
ucosal immune responses, mice were euthanized at 2 weeks post-
ooster vaccination; spleen and Peyer’s patches were removed
nd single cell suspensions were prepared as described previously
35,36].efﬁcacy compared to BALB/c mice given the control unadjuvated vaccine [34,35]
(avidity proﬁles were IL13−/− unaduvanted > BALB/c adjuvanted > BALB/c unadju-
vanted).
2.2. Tetramer and homing markers staining
Allophycocyanin (APC) conjugated KdGag197–205 tetramers
were synthesized at the Bio-Molecular Resource Facility at
JCSMR/ANU. Tetramer staining was performed as described previ-
ously [2,37]. Brieﬂy, 2 × 106 splenocytes and mucosal lymphocytes
were stained with anti-CD8-FITC antibody (BD PharMigen, San
Diego, CA) and APC conjugated KdGag197–205 tetramer at room tem-
perature for 40 min. To evaluate homing markers by ﬂow cytometry
(FACS), following tetramer staining cells were also surface stained
with biotin labeled anti-mouse 47 (e-Biosciences, USA), PE
conjugated anti-mouse L2 (Biolegend, USA), FITC conjugated
anti-mouse CCR9 (Biolegend, USA) and/or anti-mouse CD29/1
(Biolegend, USA) antibodies for 25 min  at 4 ◦C, followed by bril-
liant violet 421 streptavidin (Biolegend, USA) for 25 min  at 4 ◦C.
Cells were ﬁxed and total 106 events per sample were collected
using Fortessa ﬂow cytometer (Becton-Dickinson), and results were
analyzed using Cell Quest Pro software.
2.3. Evaluation of single-cell mRNA expression proﬁles using
Fluidigm 48.48 Dynamic arrays
KdGag197–205 tetramer+ CD8+ single cells from spleen
and/Peyer’s patches were sorted1 using cell FACS Aria I (BD
Biosciences) into 96-well plates containing CellsDirect qRT-PCR
reaction buffer (Invitrogen), Platinum Taq polymerase/SuperScript
III reverse transcriptase (Invitrogen), a mixture of Taqman primer-
probes at 0.2× concentration speciﬁc for the transcripts of interest,
as listed in Supplementary Table 1 (Applied Biosystems), and
SuperaseIn RNase inhibitor. Immediately following cell sorting,
samples were centrifuged, and subjected to 20 cycles of pre-
ampliﬁcation using polymerase chain reaction (PCR) (cell cycling
as: 1× 50 ◦C 15 min  for the reverse transcription, 1× 95 ◦C 2 min for
reverse transcriptase inactivation and Taq polymerase activation,
followed by 20 cycles 95 ◦C 15 s and 60 ◦C 4 min  ampliﬁcation
cycle). Subsequently, the pre-ampliﬁed single-cell cDNA was1 NOTE: The purity of these cells was 99% as stringent gating was  used to deter-
mine CD8+ tetramer+ cells as done in our previous studies in spleen [2,35] and Peyer’s
patches [35,68]. Also, non HIV-speciﬁc tetramer is used as a negative control to
clearly established that the double positive cells detected are true HIV-speciﬁc CD8
T cells.
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ioMark 48.48 Dynamic array nanoﬂuidic chip (Fluidigm Inc.,
SA) according to manufacturer’s instruction (see Supplementary
luidigm section for chip loading).
.4. Statistical analysis
Ampliﬁcation signals were analyzed and Ct values were deter-
ined using Fluidigm’s real-time PCR analysis software version
. In a preliminary analysis, Ct values were dichotomised based
n the presence/absence of gene expression and the number of
ells expressing a particular gene [38] in the groups indicated
n Supplementary Table 1 were then compared using Fisher’s
xact test with SPSS (Statistical Package for the Social Sciences,
nternational Business Machine Corp., USA) version 21.0 [39].
rincipal components analysis (PCA) was used to assess patterns
f mRNA expression levels of genes, and expression level/poly-
unctionality was analyzed using a Matlab software package [40]
see Supplementary information section for more details). FACS
ata the standard error of the mean and p values were determined
sing one-way analysis of variance followed by Bonferroni’s post
ests for comparison of selected pairs in GraphPad Prism software
ersion 5.
. Results
.1. IL-13R˛2 and IL-4R antagonist adjuvanted HIV vaccines can
nduce distinct mRNA expression proﬁles in
ut-KdGag197–205-speciﬁc CD8+ T cells
The gut-KdGag197–205-speciﬁc single cells obtained from novel
L-13R2 and IL-4R antagonist adjuvanted HIV vaccinated groups
howed distinct mRNA expression proﬁles (Supplementary Fig. 1c
nd d) compared to the WT  or IL-13 KO animals that received the
tandard unadjuvanted vaccination (Supplementary Fig. 1a and b).
nlike cytokine expression, selected chemokines/their receptors,
erforin, granzymes and integrin expression patterns were signif-
cantly different between the four vaccination groups tested.
Firstly, when quantitative analysis was performed as a per-
entage of single gut KdGag197–205-speciﬁc CD8+ T cells expressing
he mRNAs of interest, at the chemokine level mRNA expression
ierarchy of RANTES > MIP-1 > MIP-1 was detected between the
our vaccination groups tested (Fig. 1a). The number of RANTES
xpressing gut KdGag197–205-speciﬁc CD8+ cells was  signiﬁcantly
igher in the IL-4R antagonist adjuvanted vaccinated group (83%)
nd the IL-13 KO mice (89%) given the unadjuvanted vaccine
ompared to the WT  BALB/c mice (66%) (unadjuvanted vaccine
s. IL-13 KO p = 0.008; unadjuvanted vaccine vs. IL-4R antago-
ist vaccine p = 0.016) (Fig. 1a). The CCR5 also displayed a similar
xpression proﬁle to RANTES where unadjuvanted vaccine vs.
L-13 KO p = 0.001; unadjuvanted vaccine vs. IL-4R antagonist vac-
ine p = 0.019 (Fig. 1a). Even though no statistical signiﬁcance was
bserved, IL-13R2 adjuvanted group also showed greater increase
n both RANTES and CCR5 compared to the control unadjuvanted
roup.
Next, when the numbers of granzymes and perforin express-
ng cells (critical mediators of anti-viral cytotoxic immunity) were
valuated, 10–40% gut KdGag197–205-speciﬁc CD8+ T cells were
ound to express granzymes A and B, while 60–80% expressed per-
orin, and no granzyme C was detected in all four groups tested,
here the expression hierarchy was perforin > granzymes A and BFig. 1b). Interestingly, the perforin mRNA expression proﬁle was
igniﬁcantly different between WT mice and IL-13 KO mice that
eceived the unadjuvanted vaccine (p = 0.009) unlike the group that
eceived the adjuvanted vaccines (Fig. 1b). (2015) 7315–7327 7317
Unlike transient inhibition of IL-13 (IL-13R2 adjuvanted
vaccine), the complete absence of IL-13 (e.g. IL-13 KO mice) sig-
niﬁcantly reduced the number of gut KdGag197–205-speciﬁc CD8+
T cells expressing the memory differentiation marker CD62L (L-
selectin/Sell) (WT  vs. IL-13 KO *p = 0.020) and activation marker
CD69 (WT  vs. IL-13 KO **p = 0.002) (Fig. 1c), but enhanced expres-
sion of P-selectin ligand or Selplg (WT  vs. IL-13 KO *p = 0.017) were
detected. No signiﬁcant differences in CD62L, P-selectin ligand,
CCR7 or CD69 mRNA expression were found in BALB/c mice given
the unadjuvanted or adjuvanted vaccines (Fig. 1c).
3.2. IL-13 inhibition can induce distinct integrin mRNA
expression proﬁles in gut-KdGag197–205-speciﬁc CD8+ T cells
Since an effective vaccine against HIV-1 should have the abil-
ity to recruit antigen-speciﬁc effector CD8+ T cells to the mucosae,
next the integrin expression proﬁles were evaluated. Knowing that
4 can heterodimerize with either 7 or 1, while E can only het-
erodimerize with 7, when these integrins were evaluated in gut
KdGag197–205-speciﬁc CD8+ cells, 4 and 7 mRNA were detected
in 60–90% of the cells from all groups tested (Fig. 1d). 1 mRNA
expression was similar between the BALB/c mice that received the
unadjuvanted or adjuvanted vaccines (∼40%) (Fig. 1d). However,
the IL-13 KO animals that received the unadjuvanted vaccination
showed signiﬁcantly elevated numbers of cells expressing 4 and
1 mRNA (WT  vs. IL-13 KO, *p = 0.014; WT  vs. IL-13 KO, *p = 0.017)
and signiﬁcantly reduced numbers of cells expressing E were
detected (WT  vs. IL-13 KO, *p = 0.012) compared to the wild type
animals that received the same vaccine (Fig. 1d).
2 integrin is known to heterodimerize with D, L, M or
X. Our data revealed that out of these integrins, only L and
X mRNA were detected in gut KdGag197–205-speciﬁc CD8+ T cells
(Fig. 1e). The number of gut KdGag197–205-speciﬁc CD8+ T cells that
expressed L and 2 mRNA was signiﬁcantly lower in IL-4R antag-
onist adjuvanted group compared to the BALB/c mice that received
the unadjuvanted vaccine (*p = 0.03) (Fig. 1e). Also very low num-
bers of cells were found to express in X mRNA in all groups tested
with no signiﬁcant difference.
3.3. Quantitatively distinct mRNA expression proﬁles were
observed following novel adjuvanted vaccination compared to
unadjuvanted control vaccine strategy
To establish the qualitative differences in log mRNA expression
and to identify potential mucosal-speciﬁc CD8+ T-cell biomarkers,
next the mRNA expression levels in single gut-KdGag197–205-
speciﬁc CD8+ T cells were detected using a multivariate PCA
approach (see Supplementary statistics section for details). In this
analysis, the rank-correlated expression (Fig. 2a) of 21 mRNAs was
best approximated by the four principal components (PC1, PC2, PC3
and PC4) that explained at least 75% of the total variance.
The ﬁrst principal component (PC1) explained 36% of the total
variance in overall log expression. This axis reﬂected the pattern of
positively correlated expression of RANTES, MIP1, perforin, CCR5
and integrin 4 and negatively correlated expression of CCR9, CCR7
and Sell/L-selectin (Fig. 2b). PC1 scores differentiated the adju-
vanted vaccine groups which had higher relative expression of
RANTES, MIP1, and integrin 4 and correspondingly lower rela-
tive expression of CCR9, CCR7, Sell/L-selectin and integrin E, from
the unadjuvanted vaccine group (p < 0.001) (Fig. 2b–d).
The second principal component (PC2) explained 18% of the total
variation in overall log expression. This axis reﬂected the coordi-
nated expression of MIP1, MIP1, RANTES, CCR5, granzymes A
and B, TNF- and IFN- (Fig. 2b). Mean PC2 scores differed signif-
icantly between the IL-13 KO and other vaccine groups with IL-13
KO mice showing increased expression patterns of MIP1, MIP1,
7318 S. Trivedi et al. / Vaccine 33 (2015) 7315–7327
Fig. 1. Detailed evaluation of percentage of mucosal KdGag197–205 tetramer+ CD8+ single cells expressing particular gene in different vaccine groups compared to the standard
FPV-HIV/VV-HIV vaccine. Wild type (WT) BALB/c and IL-13 gene knock out (KO) mice (n = 4–5) were immunized (i.n./i.m.) with vaccines indicated in Table 1. Fourteen days
post  boost immunization tetramer staining of Peyer’s patch samples was  performed, KdGag197–205-speciﬁc CD8+ single cells were sorted into 96-well plate (total 48 cells per
group),  and cDNA was  synthesized followed by single cell gene expression analysis using Fluidigm’s BiomarkTM real-time PCR system (Supplementary Table 1). The graphs
represent the percentages of KdGag197–205 tetramer+ CD8+ single cells (y-axis) in Peyer’s patches expressing MIP1, MIP1, RANTES and CCR5 (a), granzyme A, granzyme
B,  perforin1 (b), sell/CD62L, CCR7, selplg/P-selectin ligand and CD69 (c). The graph also shows percentage of KdGag197–205-speciﬁc CD8+ T cells expressing integrins (d, e) in
different vaccine groups. The p values were determined using Fisher’s exact statistical test (note: *p values in the box are for genes mentioned left to right on x-axis). Data
represent two experiments for standard unadjuvanted vaccine and IL-4R antagonist adjuvanted vaccine and one experiment for IL-13 KO and IL-13R2 adjuvant vaccine
group.  Note: in this study, where less than 10% of the single cells expressed the mRNA of interest, they were excluded from further analysis (example: IL-2, IL-4, IL-13, IL-17,
CCR10,  granzyme C, and integrins M and D).
S. Trivedi et al. / Vaccine 33 (2015) 7315–7327 7319
Fig. 2. PCA of KdGag197–205-speciﬁc single CD8+ T cell gene expression patterns in Peyer’s patches following different vaccinations. The rank-correlated expression of 21
mRNA’s (a) and the genes contribution in each principle component are shown (b). The co-expression levels of gene transcripts within single KdGag197–205-speciﬁc CD8+ T cell
were  analyzed in PC1 vs. PC2 component (c), PC1 vs. PC4 component (d) and PC1 vs. PC3 component (e). In each PCA plot the dot represents KdGag197–205-speciﬁc single CD8+
T cell (red: FPV-HIV IL-4C118/VV-HIV IL-4C118, n = 86/96 single cells; green: FPV-HIV IL-13R2/VV-HIV IL-13R2, n = 27/48 single cells; blue: FPV-HIV/VV-HIV IL-13 KO,
n  = 37/48 single cells; black: FPV-HIV/VV-HIV BALB/c, n = 83/96 single cells). The bold bigger dots represent mean gene expression level for different vaccine groups tested;
analysis  of variance (ANOVA) was  used to compare the primary principal component scores across the groups as mentioned in Section 2. Data represent two experiments
for  standard unadjuvanted vaccine and IL-4R antagonist adjuvanted vaccine and one experiment for IL-13 KO and IL-13R2 adjuvant vaccine group. (For interpretation of
the  references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
7320 S. Trivedi et al. / Vaccine 33 (2015) 7315–7327
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ANTES, CCR5, granzymes A and B, TNF- and IFN- compared with
he other groups (p < 0.001) (Fig. 2c). The fourth principal com-
onent (PC4) likewise described signiﬁcant differences between
L-13 KO and other vaccine groups tested and corresponded to rel-
tive low expression of CD69 and high expression of P-selectin
igand (Selplg) and perforin mRNA in IL-13 KO vaccinated group
p < 0.01) (Fig. 2b and d). The third principal component (PC3) cor-
esponded with no signiﬁcant differences between all the groups
ested (Fig. 2e).
Overall, our PCA results indicated that (i) following novel IL-
3R2 or IL-4R antagonist adjuvanted vaccination, the “level” of
RNA expression (speciﬁcally RANTES, MIP-1,  and integrin 4)
n gut KdGag197–205-speciﬁc single CD8+ T cells was  signiﬁcantly
levated compared to unadjuvanted control vaccine and (ii) the
RNA expression patterns in animals which received IL-13R2 or
L-4R antagonist adjuvanted vaccines showed signiﬁcantly differ-
nt mRNA expression proﬁles to that of IL-13 KO mice.
.4. Distinct mRNA expression proﬁles were detected in systemic
nd mucosal KdGag197–205-speciﬁc single CD8+ T cells
With the goal of identifying possible surrogate markers of effec-
ive mucosal immunity in the systemic compartment, next splenic
nd Peyer’s patch KdGag197–205-speciﬁc single CD8+ T cells were
nalyzed between unadjuvanted and IL-4R antagonist vaccinated
roups. Data revealed that the numbers of KdGag197–205-speciﬁcnued ).
CD8+ T cells that expressed RANTES and granzyme A mRNA were
signiﬁcantly higher in spleen while CD62L and CD69 were sig-
niﬁcantly higher in Peyer’s patch (Fig. 3a). Additionally, the IL-4R
antagonist adjuvanted vaccinated group also showed signiﬁcantly
elevated numbers: KdGag197–205-speciﬁc CD8+ T cells expressing
perforin (p = 0.03) and MIP-1 mRNA (p = 0.027) in spleen and
Peyer’s Patch, respectively (Fig. 3a). Similarly, in the unadjuvanted
vaccine group, Granzyme B (p = 0.021) and CCR7 (p = 0.0001) mRNA
expression was  signiﬁcantly higher in gut KdGag197–205-speciﬁc
CD8+ T cells compared to spleen. Also in gut CD62L− CCR7− effec-
tor memory (Em) phenotype was greater (80%) than CD62L+ CCR7+
central memory (Cm) KdGag197–205-speciﬁc CD8+ T-cell phenotype
(20%), no Cm CD8 T cells were detected in spleen (Fig. 3a).
3.5. Distinct integrin/CCR9 mRNA and protein expression proﬁles
were detected in systemic and mucosal KdGag197–205-speciﬁc
single CD8+ T cells
Knowing 4 can heterodimerize with 7 and 1 while E can
only heterodimerize with 7, next mRNA expression proﬁles of
these integrins in spleen and Peyer’s patch KdGag197–205-speciﬁc
single CD8+ T cells were evaluated. In both compartments, integrins
4 (80–90%) and 7 (50–70%) expressions were found to be similar
following unadjuvanted and IL-4R antagonist adjuvanted vacci-
nation (Fig. 3b). However, compared to Peyer’s patch signiﬁcant
increase in the number of splenic KdGag197–205-speciﬁc single CD8+
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Fig. 3. Evaluation of percentage of KdGag197–205-speciﬁc single CD8+ T cell expressing genes in systemic and mucosal compartments. BALB/c mice (n = 5 per group) were
immunized i.n./i.m. with standard FPV-HIV/VV-HIV vaccine or FPV-HIV IL-4C118/VV-HIV IL-4C118 vaccine. Fourteen days post boost immunization, spleen and Peyer’s
patches were harvested and single-cell suspensions prepared; following tetramer staining KdGag197–205-speciﬁc single splenic and Peyer’s patch CD8+ T cells (total of 48
cells)  were sorted from the same group of animals, cDNA was  synthesized and mRNA expression was evaluated using Fluidigm BiomarkTM real-time PCR system as mentioned
in  Section 2. The graphs (a–c) represent percentage of KdGag197–205-speciﬁc single CD8+ T cell expressing indicated genes, the x-axis A SP and A PP = spleen and Peyer’s patches
of  FPV-HIV/VV-HIV vaccinated group, D SP and D PP (gray ﬁlled) = spleen and Peyer’s patches of FPV-HIV IL-4C118/VV-HIV IL-4C118 vaccinated group. Following standard
or  novel vaccination, the percentages of tetramer-speciﬁc single CD8+ T cells expressing particular gene were compared between spleen and Peyer’s patches; signiﬁcant
differences as indicated by p-values below the graphs were determined using Fisher exact’s test. Standard unadjuvanted vaccine represents one experiment and IL-4R
antagonist adjuvanted vaccine represents data from two experiments. The spleen and Peyer’s patches were harvested from same experiment and the statistical signiﬁcance
is  shown between the two compartments within a vaccination group.
7322 S. Trivedi et al. / Vaccine 33
Fig. 4. Evaluation of integrin protein expression in KdGag197–205-speciﬁc CD8+ T cells
in  spleen and/Peyer’s patches using ﬂow-cytometry. BALB/c mice (n = 4 per group)
were immunized i.n./i.m. with standard unadjuvanted vaccine or IL-4R antagonist
adjuvanted vaccine, 14 days post boost immunization spleen and Peyer’s patches
were collected (note: Peyer’s patches were pooled from all animals), tetramer and
homing marker staining was performed as mentioned in Section 2, and the per-
centages of KdGag197–205-speciﬁc CD8+ T cells that expressed integrin 47 (a), 1
(b),  L2 (c), and CCR9 (d) were analyzed in spleen and Peyer’s patches using ﬂow-
cytometry. The x-axis A SP and A PP = spleen and Peyer’s patches of FPV-HIV/VV-HIV
vaccinated group, D SP and D PP (gray ﬁlled) = spleen and Peyer’s patches of FPV-HIV
IL-4C118/VV-HIV IL-4C118 vaccinated group, error bars indicate standard error of
mean, the p values for multiple comparisons were obtained from one-way analysis
of  variance followed by Bonferroni’s post hoc tests. Data for gut-speciﬁc homing
markers expression 47 and CCR9 by tetramer+ CD8+ T cells represent average of
5–7 experiments and for integrins L2 and 1 represent 2–3 experiments. Note:
%  KdGag197–205-speciﬁc CD8+ T cells in spleen = 5–6% for standard FPV-HIV/VV-HIV
vaccine and 10–12% for IL-4R antagonist vaccine; % KdGag197–205-speciﬁc CD8+ T
cells in Peyer’s patches = 0.5–1.5% for standard FPV-HIV/VV-HIV vaccine and 2–3%
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and (iv) FPV-HIV IL-4C118/VV-HIV IL-4C118 adjuvanted vaccinatedor  IL-4R antagonist vaccine consistent to our previous studies [34,35].
 cells that expressed integrin 1 mRNA was detected (p < 0.0001)
Fig. 3b) while, higher numbers of integrin E mRNA expressing
ells were detected in Peyer’s patch compared to spleen (p < 0.0001)
Fig. 3b) in both vaccine groups tested.
We next assessed mRNA expression of L and X which
re known to heterodiomerize with integrin 2. Although data
evealed that L and X were not signiﬁcantly different between
pleen and Peyer’s patch in both vaccine groups tested (Fig. 3c),
ompared to Peyer’s patch there was a signiﬁcant increase in
he number of splenic KdGag197–205-speciﬁc single CD8+ T cells
hat expressed integrin 2 mRNA in IL-4R antagonist vaccinated
roup (p = 0.038) (Fig. 3c). In addition to integrins, in both vaccine
roups, KdGag197–205-speciﬁc CD8+ T cells that expressed the CCR9
ere signiﬁcantly elevated in Peyer’s patch compared to spleen
p = 0.0001) (Fig. 3c). Flow cytometry analysis of KdGag197–205-
peciﬁc CD8+ T cells revealed that similar to what was observed at
he mRNA level (Fig. 3a), no signiﬁcant differences in heterodimer
47 were detected between spleen and Peyer’s patches in both
accines tested (Fig. 4a). In the IL-4R antagonist vaccine group,
he number KdGag197–205-speciﬁc CD8+ T cells that expressed 1 (2015) 7315–7327
were elevated in spleen compared to Peyer’s patch (Fig. 4b). More-
over, although there was  no signiﬁcant difference in L mRNA in
spleen and Peyer’s patch, the numbers of L2 expressing splenic
KdGag197–205-speciﬁc CD8+ T cells were signiﬁcantly elevated in
both vaccine groups tested (Fig. 4c). Our data also indicated that
unlike 47, the number of KdGag197–205-speciﬁc CD8+ T cells that
expressed CCR9 were signiﬁcantly elevated in Peyer’s patch com-
pared to spleen at both the mRNA (Fig. 3c) and protein level (Fig. 4d),
suggesting that CCR9 is more speciﬁc to gut. Collectively, the single-
cell mRNA expression analysis and ﬂow cytometry analysis clearly
indicated that following vaccination distinct gene expression pro-
ﬁles can be observed in systemic and mucosal KdGag197–205-speciﬁc
CD8+ T cells.
3.6. PCA revealed distinct mRNA expression proﬁles between
systemic and mucosal compartments
Next PCA was  performed to evaluate the differences between
spleen and Peyer’s patch. In this analysis, the rank-correlated
expression (Fig. 5a) of 21 mRNAs was best approximated by four
principal components (PC1, PC2, PC3, PC4) that explained at least
71.5% of the total variance. The PC1 explained 38% of the total
variance in overall log expression. This axis reﬂected the coor-
dinated expression of perforin, integrin 4 and 1 and also of
CD69, CCR9, MIP-1,  Sell/L-selectin and CCR7 mRNA (Fig. 5b).
PC1 scores differentiated the spleen which had relatively higher
expression of perforin, integrin 4 and 1 and lower expression
of CD69, CCR9, MIP-1,  Sell/L-selectin and CCR7 from the Peyer’s
patches of respective vaccine groups (p < 0.001) (Fig. 5c). Mean PC1
scores also differentiated adjuvanted vaccine group which had rel-
atively higher expression of perforin, integrin 4 and 1 in splenic
KdGag197–205-speciﬁc CD8+ T cells from the unadjuvanted group
(p < 0.01) (Fig. 5c).
The PC2 explained 18% of the total variance in overall log expres-
sion. This axis reﬂected the coordinated mRNA expression proﬁle of
RANTES, MIP-1,  granzyme A and B and integrin 2 (Fig. 5b). Mean
PC2 scores differed signiﬁcantly between spleens and Peyer’s patch
with relatively higher expression of this proﬁle in spleen (p < 0.001)
(Fig. 5c). The PC3 explained only 8% of the total variance in over-
all log expression. Mean PC3 scores differed signiﬁcantly between
spleen and Peyer’s patch and indicated relatively higher expression
of integrin L and lower expression of integrin 7 in spleen com-
pared to Peyer’s patches of respective vaccine groups (Fig. 5d). The
PC4 corresponded with no signiﬁcant differences between spleen
and Peyer’s patches (Fig. 5e).
3.7. The gut KdGag197–205-speciﬁc CD8+ T cells that expressed
RANTES were polyfunctional
As relatively higher proportion of gut KdGag197–205-speciﬁc
CD8+ T cells expressed RANTES in all the three groups when com-
pared to the unadjuvanted vaccination (Fig. 1a), we next evaluated
the probability of other mRNAs to co-express together with RANTES
(polyfunctionality in relation to RANTES) using the Matlab script
that was  developed. Data indicated that more than 50% of RANTES
expressing gut KdGag197–205-speciﬁc CD8+ T cells obtained from (i)
BALB/c mice given the unadjuvanted vaccine co-expressed MIP1-
, perforin, granzyme-A, integrin 4 and 7 (Fig. 6a), (ii) IL-13 KO
mice given the unadjuvanted vaccine co-expressed MIP1-, CCR5,
perforin, P-selectin ligand, integrin 4, L, 1 and 7 (Fig. 6b),
(iii) FPV-HIV IL-13R2/VV-HIV IL-13R2  adjuvanted vaccinated
group co-expressed MIP1-,  perforin, integrin 4 and 7 (Fig. 6c)group co-expressed MIP1-,  perforin, CCR5, integrin 4, 1 and
7 (Fig. 6d). In FPV-HIV/VV-HIV and FPV-HIV IL-4C118/VV-HIV
IL-4C118 vaccinated groups, KdGag197–205-speciﬁc splenic CD8+ T
S. Trivedi et al. / Vaccine 33 (2015) 7315–7327 7323
Fig. 5. PCA of KdGag197–205-speciﬁc single CD8+ T-cell gene expression patterns in spleen vs. Peyer’s patches. Following standard vaccine and/IL-4R antagonist adjuvanted
vaccination mRNA expression levels were compared in between the two tissues. The rank-correlated expression of 21 mRNA’s (a) and the genes contribution in each principle
component are shown (b). In PC1 vs. PC2 plot (c), PC1 vs. PC3 plot (d) and PC1 vs. PC4 plot (e) the dots represent KdGag197–205-speciﬁc single CD8+ T cells isolated from
Peyer’s patches and triangles represent KdGag197–205-speciﬁc single CD8+ T cells isolated from spleen. The cluster of mean gene expression levels is indicated as ﬁlled black
dot:  Peyer’s patch KdGag197–205-speciﬁc CD8+ T-cell response after FPV-HIV/VV-HIV vaccination (n = 45/48 single cells); ﬁlled red dot: Peyer’s patch KdGag197–205-speciﬁc
CD8+ T cell response after FPV-HIV IL-4C118/VV-HIV IL-4C118 vaccination (n = 86/96 single cells); ﬁlled blue triangle and yellow triangle for KdGag197–205-speciﬁc CD8+ T cell
response in spleen following FPV-HIV/VV-HIV (n = 45/48 single cells) and/FPV-HIV IL-4C118/VV-HIV IL-4C118 vaccination (n = 91/96 single cells), respectively. Data represent
one  experiment with standard vaccine and two experiments with IL-4R antagonist vaccine. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web  version of the article.)
7324 S. Trivedi et al. / Vaccine 33 (2015) 7315–7327
Fig. 5. (Continued ).
Fig. 6. Following different vaccinations, analysis of genes that were co-expressed with RANTES within KdGag197–205-speciﬁc single CD8+ T cells. BALB/c and IL-13 KO mice
were  immunized i.n./i.m. with different vaccines as indicated (a–f), cells expressing RANTES were considered 100% and then the percentage probability of indicated genes
co-expressed with RANTES in Peyer’s patch (a–d) and spleen (e and f) were determined using Matlab software as indicated in Section 2. Data represent two experiments for
standard unadjuvanted vaccine and IL-4R antagonist adjuvanted vaccine and one experiment for IL-13 KO and IL-13R2 adjuvant vaccine group. Note: Data presented in
Figs. 1–6 were obtained from same vaccination experiment.
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ells that expressed RANTES were also found to co-express MIP1-
, perforin, integrin 4 and 7 (Fig. 6e and f) and granzyme-A and
ntegrin 1 were found to be greatly elevated in spleen compared
o Peyer’s patch (Fig. 6a, e and d, f).
Overall quantitative analysis of the data indicates that integrin
E (Fig. 3) and CCR9 (Figs. 3–6) were speciﬁc to Peyer’s patch,
nd higher proportion and relative higher expression of granzyme
 (Figs. 3–6) and integrin 2 (Figs. 3–5) were detected in spleen
ompared to Peyer’s patches. However, RANTES, MIP1-,  perforin,
ntegrin 4, 1 and 7 (Figs. 1–6) were found to be common
iomarkers detected both in Peyer’s patch and spleen (see Venn
iagram Supplementary Fig. 2).
Overall quantitative analysis of the data indicates that integrin
E (Fig. 3) and CCR9 (Figs. 3–6) were speciﬁc to Peyer’s patch,
nd higher proportion and relative higher expression of granzyme
 (Figs. 3–6) and integrin 2 (Figs. 3–5) were detected in spleen
ompared to Peyer’s patches. However, RANTES, MIP1-,  perforin,
ntegrin 4, 1 and 7 (Figs. 1–6) were found to be common
iomarkers detected both in Peyer’s patch and spleen (see Venn
iagram Supplementary Fig. 2).
. Discussion
In the current study, 21 out of the 30 mRNAs tested were differ-
ntially expressed between unadjuvanted i.n. FPV-HIV/i.m. VV-HIV
accine group compared to novel IL-13R2 and IL-4R antago-
ist adjuvanted vaccinated groups that have shown to induce
igh-avidity/poly-functional mucosal and systemic KdGag197–205-
peciﬁc CD8+ T-cell immunity [34,35]. The cytokine expression
y gut or splenic-KdGag197–205-speciﬁc single CD8+ T cells was
ot signiﬁcantly different between the groups, which is not
ntirely surprising as unstimulated (no peptide/protein encoun-
ered) KdGag197–205-speciﬁc CD8+ T cells have shown to express
o or very low IFN-, TNF- and IL-2 at the mRNA and proteins
evels [2,22]. Multiple studies have shown that following vaccina-
ion measuring the expression of not only cytokines (i.e. IFN-) but
lso chemokines, granzymes and perforin is of great importance
hen evaluating vaccine efﬁcacy [24,41]. The principal compo-
ent analysis of gut-KdGag197–205-speciﬁc single cells revealed
nhanced expression of RANTES and MIP-1 mRNA following
L-13R2 and IL-4R antagonist adjuvanted vaccination strategy
ncluding the IL-13KO mice given the unadjuvanted vaccine com-
ared to the BALB/c unadjuvanted control. This is consistent with
ur previous ﬁnding where elevated RANTES was detected in
L-13−/− and IL-4−/− splenic KdGag197–205-speciﬁc CD8+ T cells fol-
owing unadjuvanted vaccination [22]. Macaques vaccinated with
HIV-4, the expression of RANTES together with IFN-, have been
ssociated with protection against SIVsm challenge [26]. Involve-
ent of RANTES in protection has also been reported with other
hronic viral infections [42]. Moreover, in HIV non-progressors not
nly high levels of IFN- and [24] MIP-1 but also expression of
erforin by HIV-speciﬁc CD8+ T cells has been reported [43,44].
CA analysis revealed that unlike IL-13R2 adjuvanted vaccine
here IL-13 was transiently inhibited, complete lack of IL-13 (IL-
3 KO group) not only increased RANTES, MIP-1,  and perforin
RNA expression by gut-KdGag197–205-speciﬁc CD8+ T cells but
lso increased the levels of granzymes A and B mRNA expression.
Note that although the “number” of gut-KdGag197–205-speciﬁc sin-
le CD8+ T cells that expressed granzymes A and B were lower in
ll four vaccination groups tested, the “level of expression” was
igniﬁcantly elevated in IL-13KO mice that received the control
nadjuvanted vaccine, which is consistent with our previous ﬁnd-
ngs [2].] It is now established that enhanced expression of perforin
nd granzymes by CD8 T cells correlate with enhanced cytotoxi-
ity and vaccine-speciﬁc protective efﬁcacy [30,45–47]. We have (2015) 7315–7327 7325
found that IL-13 KO mice given the control unadjuvanted vaccine
were more protected against a surrogate mucosal inﬂuenza-HIV
challenge compared to BALB/c mice given the IL-13R2 adjuvanted
vaccine. This difference in protection in IL-13 KO mice could mainly
be associated with the enhanced expression of RANTES, MIP-1,
perforin and also granzymes A and B by these KdGag197–205-speciﬁc
CD8+ T cells at the mucosae (enhanced expression of cytotoxic
proteins). Interestingly, PCA revealed that the mean PC2 scores
differed signiﬁcantly between the IL-13 KO and the novel vac-
cine groups tested, highlighting the unique effects of transient
inhibition of IL-13 verses total absence of IL-13 activity at the
mucosae.
It is established that migration of lymphocytes to gut mucosae
is mediated by integrin 4 heterodimerisation with 7 chain, not
the 1 chain, and MAdCAM-1 ligand interacts preferentially with
47, not 41 [11,48], which is also consistent with our recent
ﬁndings [68] Following the adjuvanted and unadjuvanted vaccina-
tion, relatively higher numbers of gut KdGag197–205-speciﬁc CD8+
T cells were found to express 7 but not 1 mRNA, indicating that
higher numbers of antigen-speciﬁc CD8+ T cells could be trafﬁcking
to the gut mucosae. This is of importance in the context of an HIV
vaccine, as the primary site of CD4 depletion is thought to be the gut
mucosae [49,50]. In contrast, in all groups tested, increased num-
bers of 1 expressing splenic-KdGag197–205-speciﬁc CD8+ T cells as
well as elevated expression of 1 mRNA and protein were detected
in splenic-KdGag197–205-speciﬁc compared to Peyer’s patch, sug-
gesting that in spleen integrin 1 preferentially heterodimerised
with integrin 4 and not integrin 7. Interestingly, in CD4+ T cells,
elevated expression of 1 integrin subunit has shown to hamper
integrin 7 interaction with integrin 4, resulting in suppression of
47 protein expression and T-cell homing to Peyer’s patch [51].
Recently, using single-cell analysis, Kim et al. also have demon-
strated that the co-engagement of 41 together with CD8/CD4
co-receptors on human T cells can also induce robust IL-2 and IFN-
 cytokine production [52]. Elevated IL-2 and IFN- expression
by splenic-KdGag197–205-speciﬁc CD8+ T cells (post HIV-peptide
stimulation) have been detected in adjuvanted vaccinated group
compared to mice given the unadjuvanted strategy [34,35]. These
ﬁndings further indicate that integrin 1 may not only play a role
in T-cell trafﬁcking but also optimal T-cell activation and effector
function.
In murine and non-human primate models, differential regu-
lation of immune responses has been observed in systemic and
mucosal compartments [37,53–56]. Consistent to other studies
[57–59], our current data further conﬁrm that there is a clear com-
partmentalization of immune responses between the spleen and
gut compartments, even at the single cell level, highlighting the
importance of evaluating both systemic and mucosal immunity,
following mucosal vaccination. We  believe that these differences
are mainly linked to (i) the cytokine cell milieu induced following
vaccination [2,68] and (ii) the resulting innate lymphoid cell sub-
sets and antigen presenting cell subsets activated at the vaccination
site [35,60], (iii) the mode of antigen uptake and presentation that
take place via M-cells, which is exclusive to the mucosae [61,62],
(iv) plus the homing signature acquired by the resulting T cells
according to the anatomical location [68,63]. For example, it has
been shown that priming with Peyer’s patch derived DCs (but not
splenic DCs) can induce the up-regulation of 47 and CCR9 on
CD8+ T cells and licence them to migrate to the gut mucosae [64].
In this study, although 7 mRNA and 47 protein expression
levels were similar in splenic or Peyer’s patch derived KdGag197–205-
speciﬁc CD8+ T cells, signiﬁcantly elevated CCR9 expression was
detected only in gut. Interestingly, PCA revealed a negative cor-
relation of integrin 4 and CCR9 mRNA expression. MAdCAM-1
(which binds to 47) which is mainly detected in high endothe-
lial venules of Peyer’s patch is also thought to be present on
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he sinus-lining cells in the spleen [65]. Thus, this may  explain
he unexpected abundance of 47+ KdGag197–205-speciﬁc splenic
D8+ T cells observed, suggesting these may  originate from gut (cir-
ulating gut T cells) [66]. In contrast, epithelial cells in the small
ntestine exclusively express the chemokine ligand 25 (CCL25),
hich can bind to CCR9 on T cells, thereby facilitating CCR9+
-cell homing to the intestine [67]. Thus, the current data indi-
ated that compared to 47, CCR9 is more speciﬁcally involved
n gut-homing of HIV-speciﬁc CD8+ T cells. Moreover, correlated
xpression of CCR9 and integrin E was also established by PCA.
nterestingly, expression of these two molecules was  only detected
n gut-KdGag197–205-speciﬁc single CD8+ T cells, suggesting CCR9
nd integrin E could play a role in migration as well as retention
f CD8+ T cell in the intestinal mucosae [10]. It will be of inter-
st to evaluate this homing marker expression at various mucosal
ffector sites.
Data indicate that where sample size is limited, single cell Flu-
digm 48.48 Dynamic arrays can be successfully used to evaluate
accine-speciﬁc mucosal immunity. The PCA demonstrated that
ovel IL-13R2 and IL-4R antagonist adjuvanted vaccines were
niquely different compared to the WT  BALB/c control or IL-13KO
roups given the unadjuvanted vaccine, indicating that level of IL-
3 inhibition (total, transient or no inhibition) can signiﬁcantly
odulate the level of poly-functionality/cytotoxicity of CD8+ T
ells, altering the degree of T cell-mediated protective efﬁcacy.
he distinct clustering pattern of the spleen and gut KdGag197–205-
peciﬁc single CD8+ T cells, following PCA, also revealed that
ccording to the anatomical location the mRNA expression pro-
les of the 21 genes tested can be signiﬁcantly different, including
m and Cm T-cell ratios. Collectively, our analysis of the (i) relative
umbers of cells expressing the mRNAs, (ii) poly-functionality in
elation to RANTES expression and (iii) level of mRNA expression
sing PCA indicated that RANTES, MIP-1,  perforin and integrins
4, 1 and 7 could be used as a set of biomarkers to measure
ffective vaccine-speciﬁc mucosal immunity in HIV-speciﬁc single
 cells obtained from mucosal or systemic compartments.
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